Quote | Reneo Pharmaceuticals Inc. (NASDAQ:RPHM)
Last: | $1.51 |
---|---|
Change Percent: | 0.67% |
Open: | $1.48 |
Close: | $1.50 |
High: | $1.52 |
Low: | $1.48 |
Volume: | 2,199 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
News | Reneo Pharmaceuticals Inc. (NASDAQ:RPHM)
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Message Board Posts | Reneo Pharmaceuticals Inc. (NASDAQ:RPHM)
Subject | By | Source | When |
---|---|---|---|
Think we see 5 this week | heyitsmeagain | investorshub | 08/17/2022 2:10:21 PM |
Grabbed a bunch | heyitsmeagain | investorshub | 08/17/2022 11:00:00 AM |
Loaded boy Im pumped for this | heyitsmeagain | investorshub | 08/16/2022 6:40:48 PM |
A common factor among mitochondrial diseases is that | crudeoil24 | investorshub | 04/09/2021 2:14:40 PM |
Reneo Pharmaceuticals Shares Will Open For Quote At | crudeoil24 | investorshub | 04/09/2021 2:11:40 PM |
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...